NCT00461708View on ClinicalTrials.gov

A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival

PHASE2CompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Pancreatic Cancer
Interventions
DRUG

Erlotinib

100 mg, PO, once per day

DRUG

Gemcitabine

1000 mg/m2, IV, on Days 1, 8 and 15 in 4-week cycles

Trial Locations (29)

14004

Córdoba

15006

A Coruña

17007

Girona

18014

Granada

19002

Guadalajara

23007

Jaén

25198

Lleida

27004

Lugo

28040

Madrid

28041

Madrid

28922

Alcorcón

30008

Murcia

30120

Murcia

31008

Navarra

36002

Pontevedra

39008

Santander

41013

Seville

41014

Valencia

46520

Sagunto

50009

Zaragoza

03804

Alcoy

03203

Elche

07198

Palma de Mallorca

08227

Barcelona

08906

Barcelona

08907

Barcelona

08916

Barcelona

08243

Manresa

08208

Sabadell, Barcelona

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00461708 - A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival | Biotech Hunter | Biotech Hunter